Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas W Flaig

Showing results (21-30 of 142) with videos related to

Pageof 15
Sort By:
Oncology (Williston Park, N.Y.)|May 27, 2014
Metastatic relapse after initial clinical stage I testicular Leydig cell tumorNicholas G Cost, Paul Maroni, Thomas W Flaig
Nature Reviews. Clinical Oncology|November 28, 2012
Clinical opportunities and challenges in targeting tumour dormancyJonathan A Hensel, Thomas W Flaig, Dan Theodorescu
Pharmacotherapy|July 29, 2008
Bicalutamide-associated fulminant hepatotoxicityCindy L O'Bryant, Thomas W Flaig, Kenneth J Utz
Oncology (Williston Park, N.Y.)|May 22, 2013
Targeted therapy in advanced urothelial carcinomaBrandon P Verdoorn, Elizabeth R Kessler, Thomas W Flaig
Oncology Reports|September 3, 2010
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cellsYuan Li, Xiaoping Yang, Lih-Jen Su, et al.
Urologic Oncology|July 29, 2011
Low-dose diethylstilbestrol for the treatment of advanced prostate cancerJulia Clemons, L Michael Glodé, Dexiang Gao, et al.
Urology|May 3, 2011
Pazopanib synergizes with docetaxel in the treatment of bladder cancer cellsYuan Li, Xiaoping Yang, Lih-Jen Su, et al.
Clinical Lung Cancer|May 27, 2008
High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trialsKyle E Rusthoven, Thomas W Flaig, David Raben, et al.
Oncology (Williston Park, N.Y.)|January 7, 2015
Pancreatic metastases from renal cell carcinoma treated with stereotactic body radiation therapyMaría T Bourlon, Arya Amini, Brian D Kavanagh, et al.
JACC. Cardiooncology|January 13, 2023
Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded OutcomesLavanya Kondapalli, Judith Hsia, Ronni Miller, et al.
Pageof 15

Showing results (21-30 of 142) with videos related to

Sort By:
Pageof 15
Oncology (Williston Park, N.Y.)|May 27, 2014
Metastatic relapse after initial clinical stage I testicular Leydig cell tumorNicholas G Cost, Paul Maroni, Thomas W Flaig
Nature Reviews. Clinical Oncology|November 28, 2012
Clinical opportunities and challenges in targeting tumour dormancyJonathan A Hensel, Thomas W Flaig, Dan Theodorescu
Pharmacotherapy|July 29, 2008
Bicalutamide-associated fulminant hepatotoxicityCindy L O'Bryant, Thomas W Flaig, Kenneth J Utz
Oncology (Williston Park, N.Y.)|May 22, 2013
Targeted therapy in advanced urothelial carcinomaBrandon P Verdoorn, Elizabeth R Kessler, Thomas W Flaig
Oncology Reports|September 3, 2010
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cellsYuan Li, Xiaoping Yang, Lih-Jen Su, et al.
Urologic Oncology|July 29, 2011
Low-dose diethylstilbestrol for the treatment of advanced prostate cancerJulia Clemons, L Michael Glodé, Dexiang Gao, et al.
Urology|May 3, 2011
Pazopanib synergizes with docetaxel in the treatment of bladder cancer cellsYuan Li, Xiaoping Yang, Lih-Jen Su, et al.
Clinical Lung Cancer|May 27, 2008
High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trialsKyle E Rusthoven, Thomas W Flaig, David Raben, et al.
Oncology (Williston Park, N.Y.)|January 7, 2015
Pancreatic metastases from renal cell carcinoma treated with stereotactic body radiation therapyMaría T Bourlon, Arya Amini, Brian D Kavanagh, et al.
JACC. Cardiooncology|January 13, 2023
Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded OutcomesLavanya Kondapalli, Judith Hsia, Ronni Miller, et al.
Pageof 15